Peringatan Keamanan

The oral LD50 in mature rats and mice was greater than 1700 mg/kg and 600 mg/kg, respectively. Symptoms of overdose include clumsiness or unsteadiness, seizures, severe drowsiness, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath, shuffling walk, tic-like (jerky) movements of head and face, trembling and shaking of hands, and insomnia.

Azatadine

DB00719

small molecule approved

Deskripsi

Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.

Struktur Molekul 2D

Berat 290.4021
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Well absorbed after oral administration.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol.
  • 2. Take with food. Food reduces irritation.

Interaksi Obat

769 Data
Benzylpenicilloyl polylysine Azatadine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Azatadine.
Amphetamine Amphetamine may decrease the sedative activities of Azatadine.
Phentermine Phentermine may decrease the sedative activities of Azatadine.
Benzphetamine Benzphetamine may decrease the sedative activities of Azatadine.
Diethylpropion Diethylpropion may decrease the sedative activities of Azatadine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Azatadine.
Mephentermine Mephentermine may decrease the sedative activities of Azatadine.
MMDA MMDA may decrease the sedative activities of Azatadine.
Midomafetamine Midomafetamine may decrease the sedative activities of Azatadine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Azatadine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Azatadine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Azatadine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Azatadine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Azatadine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Azatadine.
Metamfetamine Metamfetamine may decrease the sedative activities of Azatadine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Azatadine.
Ritobegron Ritobegron may decrease the sedative activities of Azatadine.
Mephedrone Mephedrone may decrease the sedative activities of Azatadine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Azatadine.
Gepefrine Gepefrine may decrease the sedative activities of Azatadine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Azatadine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Azatadine.
Leuprolide The risk or severity of QTc prolongation can be increased when Azatadine is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ranolazine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Azatadine is combined with Sulfisoxazole.
Methadone The risk or severity of adverse effects can be increased when Azatadine is combined with Methadone.
Diltiazem The risk or severity of QTc prolongation can be increased when Azatadine is combined with Diltiazem.
Clozapine The risk or severity of reduced gastrointestinal motility can be increased when Azatadine is combined with Clozapine.
Sulpiride The therapeutic efficacy of Azatadine can be decreased when used in combination with Sulpiride.
Nimodipine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Nimodipine.
Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Azatadine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Prochlorperazine.
Droperidol The risk or severity of QTc prolongation can be increased when Azatadine is combined with Droperidol.
Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Azatadine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Azatadine.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ciprofloxacin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Azatadine is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Azatadine is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Cinnarizine.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Azatadine.
Chloroquine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Chloroquine.
Efavirenz The risk or severity of QTc prolongation can be increased when Azatadine is combined with Efavirenz.
Adenosine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Azatadine is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Azatadine is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Cinoxacin.
Loperamide The risk or severity of QTc prolongation can be increased when Azatadine is combined with Loperamide.
Granisetron The risk or severity of QTc prolongation can be increased when Azatadine is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Azatadine is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Mesoridazine.
Desloratadine The risk or severity of adverse effects can be increased when Azatadine is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Papaverine.
Nifedipine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Nifedipine.
Levofloxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Levofloxacin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ofloxacin.
Propafenone The risk or severity of QTc prolongation can be increased when Azatadine is combined with Propafenone.
Flecainide The risk or severity of QTc prolongation can be increased when Azatadine is combined with Flecainide.
Clarithromycin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Clarithromycin.
Mibefradil The risk or severity of QTc prolongation can be increased when Azatadine is combined with Mibefradil.
Probucol The risk or severity of QTc prolongation can be increased when Azatadine is combined with Probucol.
Aceprometazine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Aceprometazine.
Terlipressin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Terlipressin.
Prenylamine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Prenylamine.
Fluspirilene The risk or severity of QTc prolongation can be increased when Azatadine is combined with Fluspirilene.
Lofexidine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Lofexidine.
Azimilide The risk or severity of QTc prolongation can be increased when Azatadine is combined with Azimilide.
Pracinostat The risk or severity of QTc prolongation can be increased when Azatadine is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Garenoxacin.
Tedisamil The risk or severity of QTc prolongation can be increased when Azatadine is combined with Tedisamil.
Tucidinostat The risk or severity of QTc prolongation can be increased when Azatadine is combined with Tucidinostat.
Telavancin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Telavancin.
Pazopanib The risk or severity of QTc prolongation can be increased when Azatadine is combined with Pazopanib.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Azatadine is combined with Nemonoxacin.
Panobinostat The risk or severity of QTc prolongation can be increased when Azatadine is combined with Panobinostat.
Nilvadipine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Nilvadipine.
Antazoline The risk or severity of QTc prolongation can be increased when Azatadine is combined with Antazoline.
Crizotinib The risk or severity of QTc prolongation can be increased when Azatadine is combined with Crizotinib.
Bedaquiline The risk or severity of QTc prolongation can be increased when Azatadine is combined with Bedaquiline.
Fendiline The risk or severity of QTc prolongation can be increased when Azatadine is combined with Fendiline.
Eperisone The risk or severity of QTc prolongation can be increased when Azatadine is combined with Eperisone.
Butriptyline The risk or severity of adverse effects can be increased when Azatadine is combined with Butriptyline.
Ceritinib The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ceritinib.
Lenvatinib The risk or severity of QTc prolongation can be increased when Azatadine is combined with Lenvatinib.

Target Protein

Histamine H1 receptor HRH1

Referensi & Sumber

Synthesis reference: Raymond E. Dagger, Linda A. Motyka, "Process for preparing intermediates for azatidine." U.S. Patent US4954632, issued September 04, 1990.
Artikel (PubMed)
  • PMID: 8795241
    Zhang D, Hansen EB Jr, Deck J, Heinze TM, Sutherland JB, Cerniglia CE: Fungal biotransformation of the antihistamine azatadine by Cunninghamella elegans. Appl Environ Microbiol. 1996 Sep;62(9):3477-9.
  • PMID: 1982614
    Katelaris C: Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7.
  • PMID: 1968324
    Small P, Barrett D, Biskin N: Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation. Ann Allergy. 1990 Feb;64(2 Pt 1):129-31.

Contoh Produk & Brand

Produk: 2 • International brands: 3
Produk
  • Optimine Tab 1mg
    Tablet • 1 mg • Oral • Canada • Approved
  • Trinalin Repetabs
    Tablet, extended release • - • Oral • Canada • Approved
International Brands
  • Idumed — NIHFI
  • Optimine — Schering-Plough
  • Zadine — Fulford

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul